Trials / Completed
CompletedNCT01652664
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 2 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Travoprost 0.004% PQ ophthalmic solution | |
| DRUG | Timolol, 0.5% or 0.25% ophthalmic solution | Patients 2 months to \< 3 years of age received 0.25% |
| DRUG | Travoprost Vehicle | Inactive ingredients used to maintain masking |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-07-30
- Last updated
- 2015-07-23
- Results posted
- 2015-04-13
Source: ClinicalTrials.gov record NCT01652664. Inclusion in this directory is not an endorsement.